Data for ST004296   

(Analysis AN007142): Average values per metabolite and experimental factor (Units:Normalized abundance)

Metabolite structureAll dataF1F2
CE(20:5(5Z,8Z,11Z,14Z,17Z))_positive_mode
270520.00 278909.11
Cer(d18:0/26:0)_positive_mode
11774.83 16693.00
Cer(d18:1/22:1(13Z))_positive_mode
339449.33 269419.56
Cer(d18:1/24:1(15Z))_positive_mode
4798499.50 3967845.00
Cer(d18:2/23:0)_positive_mode
344108.67 251295.89
Cer(d18:2/25:0)_positive_mode
188166.83 145024.56
CL(16:0/16:0/18:0/20:4(5Z,8Z,11Z,14Z))_positive_mode
970369.17 1033805.44
CL(16:0/16:0/18:0/22:5(4Z,7Z,10Z,13Z,16Z))_positive_mode
1099436.83 914760.67
Coenzyme Q10_positive_mode
1522101.50 1435412.33
DG(14:0/24:1(15Z)/0:0)_positive_mode
12215.17 9000.44
DG(20:5(5Z,8Z,11Z,14Z,16E)-OH(18R)/i-22:0/0:0)_positive_mode
617569.67 660662.44
DG(22:0/20:5(5Z,8Z,11Z,14Z,17Z)/0:0)_positive_mode
5996260.67 6398640.78
Docosanamide_positive_mode
72565.67 62721.00
LysoPC(18:0/0:0)_positive_mode
3890958.50 3267763.44
LysoPC(18:1(11Z)/0:0)_positive_mode
413712.17 609067.67
LysoPC(20:0/0:0)_positive_mode
37975.33 40329.44
LysoPC(20:1(11Z)/0:0)_positive_mode
34628.33 40797.22
LysoPE(20:0/0:0)_positive_mode
40147.50 38795.56
LysoPE(P-18:0/0:0)_positive_mode
22553.00 16875.11
PC(O-14:0/16:0)_positive_mode
981000.00 799397.67
PC(O-14:0/16:1(9Z))_positive_mode
111204.67 103972.89
PC(P-16:0/14:0)_positive_mode
255208.83 202280.78
PE(P-16:0/22:1(13Z))_positive_mode
129508.33 122695.56
PI(16:0/20:4(8Z,11Z,14Z,17Z))_positive_mode
583386.00 392996.44
PI(18:0/20:3(8Z,11Z,14Z))_positive_mode
482441.83 294908.78
SM(d18:0/16:1(9Z))_positive_mode
77578512.17 54130331.67
SM(d18:1/17:0)_positive_mode
3595804.50 2407727.67
Sphinganine_positive_mode
3159641.17 7493913.78
Sphingosine_positive_mode
813224.17 418667.89
TG(14:0/15:0/24:0)_positive_mode
343813.67 426206.67
TG(14:0/O-18:0/20:3(5Z,8Z,11Z))_positive_mode
17947.33 15993.00
TG(24:1(15Z)/15:0/18:2(9Z,12Z))_positive_mode
293166.33 305823.22
TG(i-16:0/10:0/19:0)_positive_mode
641099.83 674406.44

Factors:

F1Sample source:hASCs | Treatment:Osteogenic conditions
F2Sample source:hASCs | Treatment:Proliferation conditions
  logo